Table 6. Prevalence of excluded triggers and ADEs.
| No. | Not-selected Triggers, n | Total ADEs | Preventable ADEs | |||
|---|---|---|---|---|---|---|
| n | PPV, % | n | PPV, % | |||
| Laboratory index | ||||||
| 1 | HGB > 170g/L(man), > 150g/L(woman) | 0 | 0 | — | 0 | — |
| 2 | Ca2+ > 2.62 mmol/L | 4 | 0 | 0.00% | 0 | 0.00% |
| 3 | TSH < 0.27 mU/L or FT4 > 22.40 pmol/L | 1 | 0 | 0.00% | 0 | 0.00% |
| 4 | TSH > 4.2mU/L or FT4 < 12.0 pmol/L | 13 | 0 | 0.00% | 0 | 0.00% |
| 5 | Clostridium difficile positive | 0 | 0 | — | 0 | — |
| Plasma concentration | ||||||
| 6 | Digoxin > 2 ng/ mL | 0 | 0 | — | 0 | — |
| 7 | Gentamicin or Tobramycin levels peak > 10mg/L, trough > 2mg/L | 0 | 0 | — | 0 | — |
| 8 | Cyclosporin > 300μg/mL | 0 | 0 | — | 0 | — |
| 9 | Theophylline > 20mg/L | 0 | 0 | — | 0 | — |
| 10 | Tacrolimus > 20 ng/mL | 0 | 0 | — | 0 | — |
| 11 | Voriconazole levels > 5.5mg/L | 0 | 0 | — | 0 | — |
| Antidotes | ||||||
| 12 | Vitamin K | 29 | 1 | 3.45% | 1 | 3.45% |
| 13 | Romazicon (Flumazenil) | 117 | 0 | 0.00% | 0 | 0.00% |
| 14 | Naloxone (Narcan) | 4 | 0 | 0.00% | 0 | 0.00% |
| 15 | 50% glucose | 0 | 0 | — | 0 | — |
| 16 | Protamine | 6 | 0 | 0.00% | 0 | 0.00% |
| 17 | Epinephrine | 230 | 2 | 0.87% | 0 | 0.00% |
| 18 | Glucose injection and regular insulin | 30 | 0 | 0.00% | 0 | 0.00% |
| 19 | Insulin (regular insulin or insulin analogue) used in non-diabetics | 2 | 0 | 0.00% | 0 | 0.00% |
| Clinical symptoms | ||||||
| 20 | Dehydration | 1 | 0 | 0.00% | 0 | 0.00% |
| 21 | Psychosis | 1 | 0 | 0.00% | 0 | 0.00% |
| 22 | Respiratory rates < 12 /min | 15 | 0 | 0.00% | 0 | 0.00% |
| Subtotal | 426 | 3 | 0.70% | 1 | 0.23% | |
HGB, hemoglobin; Ca2+, calcium; TSH, thyroid stimulating hormone; FT4, free thyroxine.